Autolus Therapeutics plc (NASDAQ:AUTL) Shares Bought by Capstone Investment Advisors LLC

Capstone Investment Advisors LLC grew its position in Autolus Therapeutics plc (NASDAQ:AUTLFree Report) by 58.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 79,374 shares of the company’s stock after acquiring an additional 29,374 shares during the period. Capstone Investment Advisors LLC’s holdings in Autolus Therapeutics were worth $506,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. purchased a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $105,000. EWA LLC raised its stake in shares of Autolus Therapeutics by 40.2% during the 4th quarter. EWA LLC now owns 25,678 shares of the company’s stock worth $155,000 after buying an additional 7,361 shares during the period. Sierra Summit Advisors LLC purchased a new position in shares of Autolus Therapeutics during the 4th quarter valued at approximately $275,000. Exchange Traded Concepts LLC grew its stake in Autolus Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 48,849 shares of the company’s stock valued at $315,000 after acquiring an additional 12,387 shares during the period. Finally, Privium Fund Management B.V. increased its holdings in Autolus Therapeutics by 43.2% in the 1st quarter. Privium Fund Management B.V. now owns 50,058 shares of the company’s stock worth $319,000 after acquiring an additional 15,091 shares in the last quarter. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Trading Down 1.1 %

Shares of NASDAQ AUTL opened at $3.45 on Monday. The firm has a 50-day simple moving average of $3.95 and a 200-day simple moving average of $5.26. Autolus Therapeutics plc has a 52 week low of $2.01 and a 52 week high of $7.45.

Autolus Therapeutics (NASDAQ:AUTLGet Free Report) last released its quarterly earnings data on Friday, May 17th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.14). The business had revenue of $10.09 million for the quarter, compared to the consensus estimate of $50.00 million. During the same period last year, the firm posted ($0.23) EPS. Analysts anticipate that Autolus Therapeutics plc will post -0.78 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. William Blair reaffirmed an “outperform” rating on shares of Autolus Therapeutics in a report on Monday, June 3rd. Truist Financial raised their price target on shares of Autolus Therapeutics from $10.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $9.00 price objective on shares of Autolus Therapeutics in a research note on Monday, June 17th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $8.70.

View Our Latest Stock Analysis on AUTL

Autolus Therapeutics Profile

(Free Report)

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.

Read More

Want to see what other hedge funds are holding AUTL? Visit to get the latest 13F filings and insider trades for Autolus Therapeutics plc (NASDAQ:AUTLFree Report).

Institutional Ownership by Quarter for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with's FREE daily email newsletter.